Background: Combination therapy of simeprevir (SIM)/sofosbuvir (SOF) is an
SVR rates of 85%-90% with this combination; however, relapse occurs in 10%-15%. 12, 13 Fixed-dose combination therapy of ledipasvir (LDV) and SOF for 8-24 weeks was approved by the FDA in October 2014 as a treatment option for hepatitis C genotype 1 patients with overall SVR rates of 97% based on the results of the ION-I, II and III trials. 14, 15 LDV targets the nonstructural phosphoprotein 5A (NS5A), which is suspected to play a role in intracellular signalling and regulation of HCV replication. 16 Since LDV targets a different site in the HCV replication cycle, it was postulated that LDV/SOF could be a retreatment option for SIM/SOF failures. Hence, we treated a cohort of hepatitis C monoinfected genotype 1 patients, including cirrhotics and liver transplant recipients, with LDV/SOF with or without RBV for 12-24 weeks to determine safety, tolerability and efficacy.
| MATERIALS AND METHODS
Data were gathered prospectively from a cohort of mono-infected chronic HCV patients treated at 2 large hepatology referral cen- were liver transplant recipients. The median baseline total bilirubin was 1.2 mg/dL, and 4 patients (13%) had a total bilirubin >2.5 mg/dL. The median baseline platelet value was 74 9 10 3 /lL and 22 patients (73%) had a platelet count <100 9 10 3 /lL. Of patients with cirrhosis, 10 had a Child's classification of A, 12 Child's B and 4 Child's C (Table 2) . Nineteen patients had a history of clinical decompensation prior to initiating the treatment and among patients with cirrhosis, the median model for end-stage liver disease (MELD) score was 10 (range, 6-22).
| RESULTS

| Treatment regimens
The median time interval between prior treatment of SIM/SOF and retreatment with LDV/SOF was 32 weeks (range, 12-54). Overall, 12 (40%) patients underwent a 12-week treatment regimen while 18 (60%) underwent a 24-week regimen. RBV was given in 43% of patients. Patients who underwent 12 weeks of therapy were more likely to receive RBV (92%) while patients who underwent 24 weeks of therapy were less likely to receive RBV (17%, P < 0.001, Table 1 ). 
| Virologic response
| Side effects
Treatment was very well tolerated with 12/30 (40%) reporting no adverse events. Side effects experienced during treatment are summarized in Table 3 . The most frequently experienced side effects were fatigue (40%), headache (27%), nausea (13%) and open-label study ASTRAL-4 for SOF/velpatasvir. However, it is important to note that both SOLAR-1 and SOLAR-2 studies only included patients who had failed prior interferon-based regimens with or without SOF but did not include prior SIM/SOF failures. 18, 19 ASTRAL-4 included patients with decompensated Child's B cirrhosis but did not include those who had failed previous NS5B inhibitor (SOF)-based regimens. 20 The multicentre, observational, prospective real-world HCV-TARGET study reported an overall SVR 12 rate of 90% in patients with decompensated cirrhosis treated with LDVSOF AE RBV for 12-24 weeks including those treated with prior DAA's. However, published data on SVR12 rates in the cohort of decompensated patients who were prior SIM/SOF failures are lacking in that study. 
| 1413
Although data were extracted prospectively from our treatment cohort, our study was limited by several factors including the absence of a control group and heterogeneity of treatment regimens.
The duration of treatment with LDV/SOF or whether to include RBV was not standardized, but left to the discretion of the treating hepatologist. Additionally, baseline NS5A resistance testing was not obtained in all patients. Despite these limitations, the findings from this study support the use of LDV/SOF with or without RBV in those who fail SIM/SOF therapy.
In summary, our real-world experience supports the use of LDV/ SOF as a safe, well-tolerated and efficacious treatment option in patients who fail prior therapy with SIM/SOF, including patients with decompensated cirrhosis and liver transplant recipients. RBV may be added to this regimen in order to achieve an optimal virologic response, particularly in those receiving 12 weeks of therapy. 
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